Stage4Hope commits $2.5 million to Memorial Sloan Kettering Cancer Center for cancer research.

Stage4Hope announced a $2.5 million multi-year commitment to Memorial Sloan Kettering Cancer Center to support translational precision oncology research led by Alexander Drilon.

Stage4Hope announced a $2.5 million multi-year commitment to Memorial Sloan Kettering Cancer Center to support translational cancer research. The funding will back work led by Alexander Drilon, MD, focusing on precision oncology and advancing discoveries into early-phase clinical trials. Stage4Hope was founded by Stacy Carter after a 2023 Stage IV lung cancer diagnosis and aims to help patients access premier cancer centers and clinical trials. The organization also provides travel assistance grants and clinical mental health retreats as part of its programs. Key details: - Funding: A $2.5 million multi-year commitment to Memorial Sloan Kettering Cancer Center. - Research lead: Alexander Drilon, MD, Chief of the Early Drug Development Service at MSK, will lead the supported translational research. - Research focus: Moving laboratory discoveries into targeted therapies and early-phase clinical trials for cancers driven by specific genetic alterations; the article mentions work related to repotrectinib, taletrectinib, and zidesamtinib. - Founder context: Stage4Hope was founded by Stacy Carter after her Stage IV lung cancer diagnosis in 2023 to help patients navigate access to advanced care. - Programs: The nonprofit partners with major cancer institutions and provides travel assistance grants and clinical mental health retreats. Summary: The commitment is intended to accelerate translational research at MSK and support efforts to move discoveries into early-phase clinical trials. MSK and Stage4Hope reported the work focuses on cancers driven by targetable genetic alterations. Undetermined at this time.